About this trial
Congenital heart disease (CHD) is the most common type of birth defect but the cause for the majority of cardiac birth defects remains unknown. Numerous epidemiologic studies have demonstrated evidence that genetic factors likely play a contributory, if not causative, role in CHD. While numerous genes have been identified by us and other investigators using traditional genetic approaches, these genes account for a minority of the non-syndromic CHDs. Therefore, we are now utilizing whole genome sequencing (WGS), with the addition of more traditional genetic techniques such as chromosomal microarray or traditional linkage analysis, to identify genetic causes of familial and isolated CHD. With WGS we are able to sequence all of the genetic material of an individual and apply different data analysis techniques based on whether we are analyzing a multiplex family or a cohort of trios (mother, father and child with CHD) with a specific isolated CHD. Therefore, WGS is a robust method for identification of novel genetic causes of CHD which will have important diagnostic and therapeutic consequences for these children.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Subjects must have a diagnosis of Congenital Heart Disease or be related to individuals with Congenital Heart Disease.
Disqualifiers
Healthy individuals unrelated to those with Congenital Heart Disease
Trial population
cardiology clinic sample, community sample
Trial design
Family-based
Prospective
Treatments tested in this trial
Blood Sample Collection
Other interventionBlood sample collection for direct sequencing, microarray, single nucleotide polymorphism, whole-genome array comparative genomic hybridization DNA analyses, and/or whole exome or genome sequencing.
Treatment groups
Trial outcomes
Primary outcomes
Identification of novel genetic contributors to congenital heart defects
Novel genetic abnormalities that are found to be associated with congenital heart defects in humans
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Nationwide Children's Hospital
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Collaborator